Agenus Inc
Most Recent
Company & Industry Overviews.Agenus: Attractive Entry Level after Recent Pullback
This year, Agenus (AGEN) stock has fluctuated widely. The clinical-stage biotechnology company’s stock fell from $3.88 in February to about $2.12 in August.
Healthcare.Will Genocea Stock Bounce Back? In-Depth Analysis
Today, we’re taking a close look at Genocea (GNCA) to show why the stock could bounce back after fluctuating significantly over the last year.
Company & Industry Overviews.Incyte Advances R&D Strategy with Multiple Partnerships
In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN).
Company & Industry Overviews.Who Is Incyte Collaborating With?
Incyte’s (INCY) Jakafi is distributed in the United States through a network of specialty pharmacy providers and wholesalers for direct delivery.
Company & Industry Overviews.Profit Taking in XBI Holdings Pulled the Fund Down
The SPDR S&P Biotech ETF (XBI) fell by 1.1% to close at $51.72 and was trading above the 20-day moving average price of $48.7.